Literature DB >> 6721448

Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.

H Ten Cate, C P Henny, H R Büller, J W Ten Cate, H N Magnani.   

Abstract

A new heparinoid, Org 10172, was given to five patients with hemorrhagic stroke with thromboembolic complications. Treatment did not cause progression of cerebral bleeding, and thrombotic processes were inhibited. No side effects were encountered.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6721448     DOI： 10.1002/ana.410150311

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  5 in total

1.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Authors:  J C Stiekema; H P Wijnand; T G Van Dinther; H C Moelker; J Dawes; A Vinchenzo; H Toeberich
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

2.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Authors:  I D Bradbrook; H N Magnani; H C Moelker; P J Morrison; J Robinson; H J Rogers; R G Spector; T Van Dinther; H Wijnand
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 3.  Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.

Authors:  M T Nurmohamed; H ten Cate; J W ten Cate
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

4.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Authors:  D P Mikhailidis; V A Fonseca; M A Barradas; J Y Jeremy; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

5.  Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.

Authors:  A de Boer; J C Stiekema; M Danhof; T G van Dinther; J K Boeijinga; A F Cohen; D D Breimer
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.